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Aim: To assess radioprotective activity of astaxanthin toward radiation-induced in vitro cytogenetic effects in human peripheral 
blood lymphocytes (PBL). Materials and Methods: PBL from the cleanup workers exposed to ionizing radiation at high doses 
in 1986 during accident on Chornobyl nuclear power plant and who were diagnosed with acute radiation sickness of the first and 
second degrees, were cultured in vitro. Astaxanthin was added into the culture medium at a final concentration of 20.0 µg/ml, 
prior to γ-irradiation of PBL in vitro at a dose of 1 Gy. The slides of metaphase chromosomes were analyzed. Results: Astaxanthin 
demonstrated considerable radioprotective effect in irradiated PBL manifested in significantly decreased levels of unstable cyto-
genetic markers of radiation exposure (dicentrics and centric rings). Conclusion: The data evidence on radioprotective capacity 
of astaxanthin toward radiation-induced cytogenetic effects in vitro in PBL of liquidators irradiated during Chornobyl nuclear 
power plant accident. This article is a part of a Special Issue entitled “The Chornobyl Nuclear Accident: Thirty Years After”.
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In April 26, 1986 the greatest technological catas­
trophe in human history — the nuclear accident at the 
Chornobyl nuclear power plant (CNPP) took place. 
In Ukraine 222,498 persons received the status of li­
quidators of this catastrophe. Among liquidators, who 
performed emergency work on the fourth power unit 
and received in the early days of the accident doses 
from 1 to 12 Gy, 134 cases of acute radiation sickness 
(ARS) were diagnosed [1]. Exposure of humans to ioni­
zing radiation is manifested primarily by the damage 
of the cell genome, which is one of the driving forces 
for various pathologies with a genetic component, 
including the malignant transformation of cells [2]. 
Therefore, protection of human genome in persons ex­
posed to ionizing radiation is extremely important task.
One of the perspective radioprotectors is astaxan­
thin — a natural carotenoid from xanthophyll group. 
It has low toxicity, high antiradical and antioxidant acti­
vity, the ability to pass through the cell membrane and 
reach the genetic apparatus in the cell nucleus [3–6]. 
However, despite a number of investigations of vari­
ous aspects of biological effects of astaxanthin, its 
possible radioprotective properties are still unknown.
It is widely accepted that the frequency of chromo­
somal aberrations in human peripheral blood lympho­
cytes (PBL) specific for ionizing radiation could serve 
as the reliable indicator of radiation mutagenesis inten­
sity. So, exactly this criterion was chosen by us to as­
sess possible gene protective properties of astaxan­
thin. Previously we discovered the ability of astaxanthin 
to decrease radiation­induced level of chromosomal 
aberrations in somatic cells of conditionally healthy 
volunteers [7]. In present study, we have evaluated 
both background (output) frequency and spectrum 
of chromosomal aberrations in PBL and cytogenetic 
effects of ionizing radiation in vitro per se and com­
bined with astaxanthin to estimate its radioprotective 
potential even for persons who recovered from ARS.
A voluntary cytogenetic examination (under con­
ditions of informed consent) was performed in two 
liquidators (V. and B. aged 73 and 76, respectively), 
in whom ARS of first and second degrees of severity 
caused by radiation exposure during emergency work 
at the reactor number four of CNPP was diagnosed 
in the NRCRM clinic in 1987. Official documented ra­
diation doses (2.0 and 2.8 Gy, respectively) for these 
persons were established in 1986. Since 1987 both 
liquidators are disabled persons of group II and have 
been annually examined and treated in the NRCRM 
clinic. In the past cytogenetic observations of these 
persons were performed by us several times — pa­
tient V. in 1996; patient B. in 1987, 1992, and 1997. 
In 2016 not only background (output) frequency and 
spectrum of chromosomal aberrations in PBL was 
defined, but also cytogenetic effect under separate 
and compatible action of astaxanthin and ionizing 
radiation in vitro.
For cytogenetic studies a conventional classical test 
system, human PBL cultured for 48 h, was used. Asta­
xanthin (Sigma, USA) was introduced into the culture 
medium in an optimal concentration of 20.0 µg/ml, 
defined during our previous studies, at early G0 stage 
of the first mitotic cycle before beginning the PBL in­
cubation, prior to γ­irradiation using emitter IBL­237C 
(with the capacity of 2.34 Gy/min) at a dose of 1.0 Gy 
[7]. The cytogenetic analysis accounted all aberrations 
of chromatid (single fragments, chromatid exchanges) 
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and chromosome (free double fragments, acentric 
rings, dicentric and ring chromosomes, abnormal 
monocentrics) types, which can be recognized on uni­
formly stained slides of metaphase chromosomes [8].
The results of cytogenetic analyses are shown in Ta­
bles 1 and 2. The data presented in Table 1 demonstrate 
a gradual decline over time of the overall frequency 
of chromosomal aberrations in the exposed individuals, 
mainly due to the elimination of specific cytogenetic 
markers of radiation exposure — as unstable (dicentrics 
and centric rings) as well as stable (abnormal mono­
centrics) aberrations of chromosome type. However, 
under the cytogenetic survey in 2016, the tendency 
for increased level of free acentrics (single and double 
fragments) was found, which permit to suggest the 
development of hidden chromosomal instability [9].
For detection of the possible hidden chromosomal 
instability and comparison of individual radiosensitivity, 
the radiation in vitro exposure of PBL cultures obtained 
from surveyed persons was conducted. As seen from 
the data presented in Table 2, under in vitro irradiation 
of PBL cultures the elevation of cytogenetic effects 
up to 25.71 ± 2.61 and 32.56 ± 2.69 aberrations per 
100 metaphases in liquidators B. and V., respectively, 
was revealed. In both persons chromosome types 
of aberrations were dominant, which is typical for 
chromosomal mutagenesis under the radiation 
exposure in G0 phase of mitotic cycle. In the 
irradiated in vitro cultures the individual frequencies 
of unstable radiogenic markers (total dicentric and 
ring chromosomes) increased up to 18.22 ± 2.30 and 
22.04 ± 2.38 per 100 metaphases in patients B. and V., 
respectively. Also, the frequency of chromosome 
type acentrics increased significantly (total number 
of double fragments and acentric rings increased 
up to 5.71 ± 1.38 and 9.20 ± 1.65 per 100 metaphases 
in liquidators B. and V., respectively). These data may 
indicate the rise of radiosensitivity in “high­doses liqui­
dators” in delayed terms after irradiation. It should 
be noted that the data on in vitro tests of liquidator V. 
with lower official dose and lower ARS degree, indi­
cated his higher radiosensitivity.
Results of astaxanthin impact on radiation­induced 
in vitro cytogenetic effects are presented in Table 2, and 
showed the significant (p < 0.01) reduction of the total 
frequency of chromosomal aberrations (from 25.71 ± 
2.61 to 15.30 ± 2.09 and from 32.56 ± 2.69 to 18.42 ± 
2.12 per 100 metaphases in patients B. and V., respec­
tively) due to significant (p < 0.01) decrease of clas­
sical radiogenic markers (dicentric and ring chromo­
somes) — from 18.22 ± 2.30 to 4.08 ± 1.89 and from 
22.04 ± 2.38 to 7.89 ± 1.54 per 100 metaphases in pa­
tients B. and V., respectively. The effectiveness of ra­
dioprotective activity of astaxanthin according to these 
indicators was ~78% and 64% in patients B. and V., 
respectively under ~82% in unexposed group of healthy 
donors. However, almost unchanged (p > 0.05) total 
frequencies of acentrics (7.49 ± 1.57 vs 9.86 ± 1.73 аnd 
9.21 ± 1.65 vs 10.43 ± 1.75 per 100 metaphases in pa­
tients B. and V., accordingly) and appearance of ab­
normal monocentrics in liquidator B. (1.36 ± 0.67 per 
100 metaphases) may testify both persistence of hidden 
chromosomal instability in remote terms after high­dose 
irradiation and increase of individual radiosensitivity 
in particular because of multiple X­ray examinations 
of ARS convalescences for a long time.
It should be noted that radioprotective activity 
of astaxanthin in PBL of persons recovered from ARS 
is lower than in PBL of healthy persons (total frequency 
of chromosome type aberrations is 66% vs 43% and 
48%, respectively) (see Table 2). These data suggest 
that activity of the repair systems in post­ARS persons 
is reduced even in delayed terms following high­dose 
irradiation.
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fragments
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Double 
fragments Dicentrics
Centric 
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Abnormal 
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